Claims for Patent: 10,342,962

Summary for Patent: 10,342,962

Title:	Abrading balloon catheter for extravasated drug delivery
Abstract:	A method of extravaated drug delivery is disclosed, including inserting a catheter with a first balloon, a second balloon, and a third balloon positioned between the first and second balloons and having a wall with an abrasive outer surface, into a bodily cavity, inflating the first and second balloons to create a chamber therebetween, stimulating a flow of blood cells by inflating the third balloon until the abrasive outer surface abrades tissue, and delivering the agent to the chamber. A balloon catheter system is also provided including a balloon having a wall with an abrasive outer surface for abrading tissue, a catheter having a first lumen for supplying fluid to the balloon to inflate the balloon such that the abrasive surface stimulates a flow of blood cells, and a second lumen for supplying an agent to tissue.
Inventor(s):	Gerrans; Lawrence J. (San Anselmo, CA), Gunday; Erhan H. (Great Neck, NY)
Assignee:	Sanovas Intellectual Property, LLC (Reno, NV)
Application Number:	15/841,183
Patent Claims:	1. A method of extravasated delivery of a therapeutic and/or diagnostic agent to tissue, comprising the steps of: inserting a catheter into a bodily cavity, said catheter comprising a first balloon; a second balloon; a third balloon positioned between the first and second balloons and having a wall with an abrasive outer surface; and at least one additional balloon positioned between the first and second balloons and having a wall with an abrasive outer surface; inflating the first and second balloons to create a chamber between the first balloon and the second balloon, wherein the boundaries of the chamber are defined by an inner surface of the cavity wall and the catheter; stimulating a flow of blood cells by repeatedly inflating and deflating the third balloon by supplying fluid to the third balloon such that the abrasive outer surface abrades tissue in the bodily cavity as the third balloon is repeatedly inflated and deflated; and delivering at least one of a therapeutic and/or diagnostic agent to the chamber and external of the third balloon after stimulating the flow of blood cells. 2. The method of claim 1, wherein the abrasive outer surface of the third balloon comprises a mesh affixed to the wall of the third balloon. 3. The method of claim 1, wherein the first balloon and the second balloon each have a wall with a mesh affixed thereto, and wherein the step of inflating the first and second balloons further comprises contacting tissue in the bodily cavity with the mesh to prevent slippage of the surface on the tissue. 4. The method of claim 1, wherein the step of delivering at least one of a therapeutic and/or diagnostic agent comprises delivering a contrast agent. 5. The method of claim 1, wherein the step of delivering at least one of a therapeutic and/or diagnostic agent comprises delivering a biomarker. 6. The method of claim 1, wherein the step of delivering at least one of a therapeutic and/or diagnostic agent comprises delivering doxorubicin. 7. The method of claim 1, wherein the step of delivering at least one of a therapeutic and/or diagnostic agent comprises delivering paclitaxel. 8. The method of claim 1, wherein the step of delivering at least one of a therapeutic and/or diagnostic agent comprises delivering docetaxel. 9. The method of claim 1, wherein the step of delivering at least one of a therapeutic and/or diagnostic agent comprises delivering a biological response modifier. 10. The method of claim 9, wherein the biological response modifier comprises an interferon. 11. The method of claim 9, wherein the biological response modifier comprises an interleukin. 12. The method of claim 9, wherein the biological response modifier comprises a colony-stimulating factor. 13. The method of claim 9, wherein the biological response modifier comprises a monoclonal antibody. 14. The method of claim 1, wherein the step of delivering at least one of a therapeutic and/or diagnostic agent comprises delivering rituximab. 15. The method of claim 1, wherein the step of delivering at least one of a therapeutic and/or diagnostic agent comprises delivering bevacizumab. 16. The method of claim 1, wherein the step of delivering at least one of a therapeutic and/or diagnostic agent comprises delivering trastuzumab. 17. The method of claim 1, wherein the step of delivering at least one of a therapeutic and/or diagnostic agent comprises delivering a tyrosine kinase inhibitor. 18. The method of claim 1, wherein the step of delivering at least one of a therapeutic and/or diagnostic agent comprises delivering drug eluting microspheres. 19. The method of claim 18, wherein the drug eluting microspheres contain paclitaxel. 20. The method of claim 18, wherein the drug eluting microspheres contain doxorubicin.

Details for Patent 10,342,962

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2039-07-19
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-07-19
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-07-19
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-07-19